View Item 

Show simple item record

Predictors and Interrelationship of Patient-Reported Outcomes in Antiphospholipid Syndrome: A Cross-Sectional Study
dc.contributor.authorWeiner, Julia K.
dc.contributor.authorSmith, Tristin
dc.contributor.authorHoy, Claire K.
dc.contributor.authorSarosh, Cyrus
dc.contributor.authorMadison, Jacqueline A.
dc.contributor.authorAmbati, Amala
dc.contributor.authorTambralli, Ajay
dc.contributor.authorPeters, Noah
dc.contributor.authorPackel, Corinne
dc.contributor.authorGockman, Kelsey
dc.contributor.authorZuo, Yu
dc.contributor.authorBriceño, Emily M.
dc.contributor.authorNagaraja, Vivek
dc.contributor.authorKnight, Jason S.
dc.date.accessioned2023-02-01T18:58:16Z
dc.date.available2024-02-01 13:58:14en
dc.date.available2023-02-01T18:58:16Z
dc.date.issued2023-01
dc.identifier.citationWeiner, Julia K.; Smith, Tristin; Hoy, Claire K.; Sarosh, Cyrus; Madison, Jacqueline A.; Ambati, Amala; Tambralli, Ajay; Peters, Noah; Packel, Corinne; Gockman, Kelsey; Zuo, Yu; Briceño, Emily M. ; Nagaraja, Vivek; Knight, Jason S. (2023). "Predictors and Interrelationship of Patient- Reported Outcomes in Antiphospholipid Syndrome: A Cross- Sectional Study." ACR Open Rheumatology 5(1): 28-37.
dc.identifier.issn2578-5745
dc.identifier.issn2578-5745
dc.identifier.urihttps://hdl.handle.net/2027.42/175765
dc.publisherWiley Periodicals, Inc.
dc.titlePredictors and Interrelationship of Patient-Reported Outcomes in Antiphospholipid Syndrome: A Cross-Sectional Study
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175765/1/acr211512_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175765/2/acr211512.pdf
dc.identifier.doi10.1002/acr2.11512
dc.identifier.sourceACR Open Rheumatology
dc.identifier.citedreferenceBeier M, Amtmann D, Ehde DM. Beyond depression: predictors of self-reported cognitive function in adults living with MS. Rehabil Psychol 2015; 60: 254 – 62.
dc.identifier.citedreferenceTatsuoka C, DeMarco L, Smyth KA, et al. Evaluating PROMIS physical function measures in older adults at risk for alzheimer’s disease. Gerontol Geriatr Med 2016; 2:2333721416665502.
dc.identifier.citedreferenceKekow J, Moots R, Khandker R, et al. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 401 – 9.
dc.identifier.citedreferenceYelnik CM, Kozora E, Appenzeller S. Non-stroke central neurologic manifestations in antiphospholipid syndrome. Curr Rheumatol Rep 2016; 18: 11.
dc.identifier.citedreferenceRicarte IF, Dutra LA, Abrantes FF, et al. Neurologic manifestations of antiphospholipid syndrome. Lupus 2018; 27: 1404 – 14.
dc.identifier.citedreferenceHalawi MJ, Cote MP, Singh H, et al. The effect of depression on patient-reported outcomes after total joint arthroplasty is modulated by baseline mental health: a registry study. J Bone Joint Surg Am 2018; 100: 1735 – 41.
dc.identifier.citedreferenceBeleckas CM, Guattery J, Chamberlain AM, et al. Using Patient-Reported Outcomes Measurement Information System measures to understand the relationship between improvement in physical function and depressive symptoms. J Am Acad Orthop Surg 2018; 26: e511 – 8.
dc.identifier.citedreferenceBelizna C, Stojanovich L, Cohen-Tervaert JW, et al. Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: are they different entities? [review]. Autoimmun Rev 2018; 17: 739 – 45.
dc.identifier.citedreferenceVianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3 – 9.
dc.identifier.citedreferenceWasserman RA, Brummett CM, Goesling J, Tsodikov A, Hassett AL. Characteristics of chronic pain patients who take opioids and persistently report high pain intensity. Reg Anesth Pain Med 2014; 39: 13 – 7.
dc.identifier.citedreferenceSalinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 2010; 74: 755 – 61.
dc.identifier.citedreferenceSalimzade A, Hosseini-Sharifabad A, Rabbani M. Comparative effects of chronic administrations of gabapentin, pregabalin and baclofen on rat memory using object recognition test. Res Pharm Sci 2017; 12: 204 – 10.
dc.identifier.citedreferenceLeach JP, Girvan J, Paul A, et al. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997; 62: 372 – 6.
dc.identifier.citedreferenceRandolph JJ, Arnett PA, Higginson CI. Metamemory and tested cognitive functioning in multiple sclerosis. Clin Neuropsychol 2001; 15: 357 – 68.
dc.identifier.citedreferenceStewart A, Collins B, Mackenzie J, et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 2008; 17: 122 – 30.
dc.identifier.citedreferenceRosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol 2015; 19: pyv082.
dc.identifier.citedreferenceJones NP, Siegle GJ, Muelly ER, et al. Poor performance on cognitive tasks in depression: doing too much or not enough? [research article]. Cogn Affect Behav Neurosci 2010; 10: 129 – 40.
dc.identifier.citedreferencePetersen JZ, Porter RJ, Miskowiak KW. Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression. J Affect Disord 2019; 246: 763 – 74.
dc.identifier.citedreferenceMaor Y, Olmer L, Mozes B. The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients: the role of depression. Mult Scler 2001; 7: 131 – 5.
dc.identifier.citedreferenceLau SC, Connor LT, Baum CM. Subjective and objective assessments are associated for physical function but not cognitive function in community-dwelling stroke survivors. Disabil Rehabil 2021. E-pub ahead of print.
dc.identifier.citedreferenceHutchinson AD, Hosking JR, Kichenadasse G, et al. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 2012; 38: 926 – 34.
dc.identifier.citedreferenceMehnert A, Scherwath A, Schirmer L, et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007; 66: 108 – 18.
dc.identifier.citedreferenceLachman ME. Development in midlife. Annu Rev Psychol 2004; 55: 305 – 31.
dc.identifier.citedreferenceAkbar N, Honarmand K, Feinstein A. Self-assessment of cognition in multiple sclerosis: the role of personality and anxiety. Cogn Behav Neurol 2011; 24: 115 – 21.
dc.identifier.citedreferenceKinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology 2010; 24: 573 – 80.
dc.identifier.citedreferenceHonarmand K, Akbar N, Kou N, et al. Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite. J Neurol 2011; 258: 244 – 9.
dc.identifier.citedreferenceNakling AE, Aarsland D, Næss H, et al. Cognitive deficits in chronic stroke patients: neuropsychological assessment, depression, and self-reports. Dement Geriatr Cogn Dis Extra 2017; 7: 283 – 96.
dc.identifier.citedreferenceDuits A, Munnecom T, van Heugten C, et al. Cognitive complaints in the early phase after stroke are not indicative of cognitive impairment. J Neurol Neurosurg Psychiatry 2008; 79: 143 – 6.
dc.identifier.citedreferenceAhluwalia J, Sreedharanunni S. The laboratory diagnosis of the antiphospholipid syndrome. Indian J Hematol Blood Transfus 2017; 33: 8 – 14.
dc.identifier.citedreferenceSchreiber K, Hunt BJ. Pregnancy and antiphospholipid syndrome. Semin Thromb Hemost 2016; 42: 780 – 8.
dc.identifier.citedreferenceGardiner C, Hills J, Machin SJ, et al. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013; 22: 18 – 25.
dc.identifier.citedreferenceMiyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295 – 306.
dc.identifier.citedreferenceErkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010; 19: 424 – 7.
dc.identifier.citedreferenceBearne LM, Bieles J, Georgopoulou S, et al. Fatigue in adults with primary antiphospholipid syndrome: findings from a mixed-methods study. Lupus 2020; 29: 924 – 33.
dc.identifier.citedreferenceGeorgopoulou S, Efraimidou S, MacLennan SJ, et al. Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36. Lupus 2015; 24: 174 – 9.
dc.identifier.citedreferenceDe Oliveira Vaz C, de Moraes Mazetto Fonseca B, Nascimento Silva Vasconcelos PE, et al. Self-perceived quality of life of primary antiphospholipid syndrome patients using vitamin K antagonist. Lupus 2021; 30: 707 – 14.
dc.identifier.citedreferenceChighizola CB, Crisafulli F, Hoxha A, et al. Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). Clin Exp Rheumatol 2021; 39: 938 – 46.
dc.identifier.citedreferenceAmigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus 2015; 24: 927 – 34.
dc.identifier.citedreferenceTorricelli AK, Ugolini-Lopes MR, Bonfa E, et al. Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus. Lupus 2020; 29: 256 – 62.
dc.identifier.citedreferenceMedina G, Cime Ake EA, Vera-Lastra O, et al. Damage index for antiphospholipid syndrome during long term follow-up: correlation between organ damage accrual and quality of life. Lupus 2021; 30: 96 – 102.
dc.identifier.citedreferenceRadin M, Foddai SG, Cecchi I, et al. Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS). Eur J Intern Med 2021; 92: 134 – 6.
dc.identifier.citedreferenceFleetwood T, Cantello R, Comi C. Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy. Front Neurol 2018; 9: 1001.
dc.identifier.citedreferenceCella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care 2007; 45 Suppl 1: S3 – 11.
dc.identifier.citedreferenceKhanna D, Maranian P, Rothrock N, et al. Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic. Value Health 2012; 15: 128 – 34.
dc.identifier.citedreferenceBartlett SJ, Orbai AM, Duncan T, et al. Reliability and validity of selected PROMIS measures in people with rheumatoid arthritis. PLoS One 2015; 10: e0138543.
dc.identifier.citedreferenceNagaraja V, Mara C, Khanna PP, et al. Establishing clinical severity for PROMIS measures in adult patients with rheumatic diseases. Qual Life Res 2018; 27: 755 – 64.
dc.identifier.citedreferenceRothrock NE, Cook KF, O’Connor M, et al. Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting. Qual Life Res 2019; 28: 3355 – 62.
dc.identifier.citedreferenceHanauer DA, Mei Q, Law J, et al. Supporting information retrieval from electronic health records: a report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform 2015; 55: 290 – 300.
dc.identifier.citedreferenceRadin M, Sciascia S, Erkan D, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum 2019; 49: 464 – 8.
dc.identifier.citedreferenceGladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363 – 9.
dc.identifier.citedreferenceKatz P, Pedro S, Michaud K. Performance of the Patient-Reported Outcomes Measurement Information System 29-item profile in rheumatoid arthritis, osteoarthritis, fibromyalgia, and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2017; 69: 1312 – 21.
dc.identifier.citedreferenceHinchcliff ME, Beaumont JL, Carns MA, et al. Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis. J Rheumatol 2015; 42: 64 – 72.
dc.identifier.citedreferenceSenders A, Hanes D, Bourdette D, et al. Reducing survey burden: feasibility and validity of PROMIS measures in multiple sclerosis. Mult Scler 2014; 20: 1102 – 11.
dc.identifier.citedreferenceBecker H, Stuifbergen A, Lee H, et al. Reliability and validity of PROMIS cognitive abilities and cognitive concerns scales among people with multiple sclerosis. Int J MS Care 2014; 16: 1 – 8.
dc.identifier.citedreferenceKasturi S, Szymonifka J, Burket JC, Berman JR, Kirou KA, Levine AB, et al. Validity and reliability of Patient Reported Outcomes Measurement Information System computerized adaptive tests in systemic lupus erythematosus. J Rheumatol 2017; 44: 1024 – 31.
dc.identifier.citedreferenceVon dem Knesebeck O, Bickel H, Fuchs A, et al. Social inequalities in patient-reported outcomes among older multimorbid patients: results of the MultiCare cohort study. Int J Equity Health 2015; 14: 17.
dc.identifier.citedreferenceBernstein DN, Mayo K, Baumhauer JF, et al. Do patient sociodemographic factors impact the PROMIS scores meeting the patient-acceptable symptom state at the initial point of care in orthopaedic foot and ankle patients? [research article]. Clin Orthop Relat Res 2019; 477: 2555 – 65.
dc.identifier.citedreferenceBraveman P, Gottlieb L. The social determinants of health: it’s time to consider the causes of the causes. Public Health Rep 2014; 129 Suppl 2: 19 – 31.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr211512_am.pdf
Size:
677.2KB
Format:
PDF
View/Open
Name:
acr211512.pdf
Size:
502.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.